Irish back obesity-battling peptide encapsulation

- Last updated on GMT

Irish back obesity-battling peptide encapsulation

Related tags: Diabetes mellitus, Insulin, Diabetes mellitus type 2

Irish biotech player AnaBio Technologies is promoting its peptide encapsulation methods for weight management diabetes-focused applications.

AnaBio is part of the Teagasc Moorepark Food Research Centre​ in Cork in southern Ireland and says its patented technology can boost oral delivery of peptides.

AnaBio said its method promoted the release of ‘satiety hormones’ and signaling peptides like glucagon-like peptide (GLP-1) and cholecystokinin (CCK) in the gut.

It said the technology could also deliver peptides to specific gut targets.

“Hence, this encapsulation system provides a novel dietary tool to control appetite and food intake,”​ it said.

Research shows that GLP-1 and CCK delay gastric emptying and promote a feeling of satiety.

“As a result, methods of enhancing GLP-1 secretion and oral peptide delivery has gained credibility from food formulators for the treatment of obesity and type-II diabetes. However, several major obstacles hinder oral peptide delivery as it is sensitive to stomach acid and enzymes.”

“So GLP-1 requires added protection to succeed as a credible treatment for type-II diabetes or obesity.”

The encapsulation method offered potential to allow GLP-1 to be, “administered in low doses, earlier and more efficiently in the progression of obesity and type II diabetes, which potentially broadens the market.”

“The technology also generates capsules with a muco-adhesive surface to enable prolonged hormone secretion and peptide residence time at the systemic target site.”

Related news

Show more

Related products

show more

Weight Management – New published clinical study

Weight Management – New published clinical study

Fytexia® | 20-Apr-2020 | Technical / White Paper

The benefits of Sinetrol on body composition have been supported by a new independent study on 86 South-Korean subjects. Data have been published this...

BERGAVIT™40:THE INNOVATION FOR CHOLESTEROL CONTROL

BERGAVIT™40:THE INNOVATION FOR CHOLESTEROL CONTROL

BIONAP Srl | 13-Apr-2020 | Product Brochure

THE INNOVATION AT BIONAP’S LABORATORIES NEVER STOP. BERGAVIT™ is able to reduce and control plasmatic “bad lipid” levels (total cholesterol, LDL and triglycerides)...

Related suppliers

Follow us

Products

View more

Webinars